Interim blinded safety results from ProMIS Neurosciences’ amyloid-targeting Alzheimer’s trial indicate low rates of brain bleeding and no incidences of brain swelling signals associated with more severe ARIA events. In the pooled safety readout, total ARIA was reported at 4.4%, with cases characterized as ARIA-H and no ARIA-E detected, supporting a potential safety profile versus already-approved options.